Trial Profile
Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Valganciclovir (Primary) ; Valproic acid (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 19 May 2016 New trial record